Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy

Journal of Clinical Investigation

Volumn 117, Issue 8, 2007, Pages 2233-2240

  Aiuti, Alessandro ^a   Cassani, Barbara ^a   Andolfi, Grazia ^a   Mirolo, Massimiliano ^a   Biasco, Luca ^a   Recchia, Alessandra ^b   Urbinati, Fabrizia ^b   Valacca, Cristina ^a   Scaramuzza, Samantha ^a   Aker, Memet ^c   Slavin, Shimon ^c   Cazzola, Matteo ^a   Sartori, Daniela ^d   Ambrosi, Alessandro ^e   Di Serio, Clelia ^e,f   Roncarolo, Maria Grazia ^a,f   Mavilio, Fulvio ^b,d   Bordignon, Claudio ^a,f  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e University Centre of Statistics in the Biomedical Sciences (CUSSB)   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; CD34 ANTIGEN; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; CELL LINEAGE; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; DNA INTEGRATION; DRUG SAFETY; ENZYME DEFICIENCY; GENE INSERTION; GENOME; HEMATOPOIESIS; HUMAN; HUMAN CELL; LOW DRUG DOSE; MULTIPOTENT STEM CELL; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTO ONCOGENE; RETROVIRAL INTEGRATION SITE; STEM CELL GENE THERAPY;

ADENOSINE DEAMINASE; ANTIGENS, CD34; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT; MALE; METALLOPROTEINS; MULTIPOTENT STEM CELLS; MUTAGENESIS, INSERTIONAL; RETROVIRIDAE; RISK FACTORS; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; VIRUS INTEGRATION;

EID: 34547686397     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31666     Document Type: Article

References (37)

1. Cavazzana-Calvo, M., et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:669-672.
2. Gaspar, H.B., et al. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 364:2181-2187.
3. Aiuti, A., et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2410-2413.
4. Ott, M.G., et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12:401-409.
5. Bordignon, C., and Roncarolo, M.G. 2002. Therapeutic applications for hematopoietic stem cell gene transfer. Nat. Immunol. 3:318-321.
6. Wu, X., Li, Y., Crise, B., and Burgess, S.M. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:1749-1751.
7. Mitchell, R.S., et al. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2:e234.
8. De Palma, M., et al. 2005. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 105:2307-2315.
9. Hematti, P., et al. 2004. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2:e423.
10. Laufs, S., et al. 2004. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol. Ther. 10:874-881.
11. Montini, E., et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687-696.
12. Bushman, F., et al. 2005. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3:848-858.
13. Du, Y., Jenkins, N.A., and Copeland, N.G. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 106:3932-3939.
14. Kustikova, O., et al. 2005. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 308:1171-1174.
15. Cavazzana-Calvo, M., and Fischer, A. 2007. Gene therapy for severe combined immunodeficiency: are we there yet? J. Clin. Invest. 117:1456-1465. doi:10.1172/JCI30953.
16. Hacein-Bey-Abina, S., et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:415-419.
17. Dave, U.P., Jenkins, N.A., and Copeland, N.G. 2004. Gene therapy insertional mutagenesis insights. Science. 303:333.
18. Woods, N.B., Bottero, V., Schmidt, M., von Kalle, C., and Verma, I.M. 2006. Gene therapy: therapeutic gene causing lymphoma. Nature. 440:1123.
19. Hershfield, M.S. 1998. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35:291-298.
20. Aiuti, A., et al. 2002. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med. 8:423-425.
21. Suzuki, T., et al. 2002. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32:166-174.
22. Ashburner, M., et al. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25:25-29.
23. Bordignon, C., et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 270:470-475.
24. + cells from the cord blood of ADA-deficient SCID neonates. Nat. Med. 9:463-468.
25. + cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 105:2699-2706.
26. Recchia, A., et al. 2006. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U. S. A. 103:1457-1462.
27. Baum, C., Kustikova, O., Modlich, U., Li, Z., and Fehse, B. 2006. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17:253-263.
28. Calmels, B., et al. 2005. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood. 106:2530-2533.
29. Deichmann, A., et al. 2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117:2225-2232. doi:10.1172/JCI31659.
30. Cattoglio, C., et al. 2007. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. In press.
31. Bester, A.C., et al. 2006. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 13:1057-1059.
32. Marculescu, R., Le, T., Simon, P., Jaeger, U., and Nadel, B. 2002. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites. J. Exp. Med. 195:85-98.
33. McCormack, M.P., and Rabbitts, T.H. 2004. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350:913-922.
34. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. 2006. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U. S. A. 103:11730-11735.
35. Pike-Overzet, K., et al. 2006. Gene therapy: is IL2RG oncogenic in T-cell development? Nature. 443:E5; discussion E6-E7.
36. Thrasher, A.J., et al. 2006. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 443:E5-E6; discussion E6-E7.
37. Kim, H.J., et al. 2000. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood. 96:1-8.